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INTRODUCTION
The interest in erythropoietin (EPO) as
a neuroprotective mediator has grown
since it was found that systemically ad-
ministered EPO crosses the blood brain
barrier and is protective in several ani-
mal models of disease, including cerebral
and spinal cord traumatic or ischemic in-
jury and peripheral neuropathies (1,2).
EPO administration reduced damage-
induced neuroinflammation, a common
component of all these diseases (3), sug-
gesting that EPO anti-inflammatory ac-
tion might be important in its pharmaco-
logical activity. This hypothesis also is
supported by the fact that administration
of EPO is effective in experimental auto-
immune encephalomyelitis (EAE), an an-
imal model for multiple sclerosis (MS),
and a model of inflammatory disease of
the central nervous system (CNS) (1,4–6).
The importance of this observation was
stressed by a clinical trial with EPO in
MS patients (7).
These findings raised the question of
the expression of endogenous EPO in
CNS diseases. EPO typically is induced
via the hypoxia-inducible transcription
factor (HIF)-1 and HIF-2, and its eleva-
tion mediates the increased production
of erythrocytes in hypoxic conditions (8).
While originally thought to be produced
only by the kidney, many tissues now are
recognized as expressing EPO (8,9).
In the CNS, EPO is produced following
cerebral ischemia (10,11), and plays a cru-
cial role in neuronal survival and in me-
diating ischemic preconditioning (12, 13).
Microarray studies in MS brain re-
vealed upregulation of genes involved in
neural protective mechanisms known to
be induced upon ischemic precondition-
ing, including HIF-1α and vascular en-
dothelial growth factor (VEGF) receptor
1 (14). In addition, expression of HIF-1α
has been found in brain lesions of a sub-
type of MS cases (15), suggesting that a
hypoxia-like tissue injury may play a
pathogenic role in MS.
Therefore, we investigated the expres-
sion of EPO in the spinal cord of mice
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using two models of EAE: a chronic
model induced in C57BL/6 mice by im-
munization against a peptide of myelin
oligodendrocyte glycoprotein (MOG)
(6), and a relapsing-remitting model
induced in SJL mice by immunizing
against myelin proteolipid protein (PLP)
peptide (16). Since we found that EPO is
co-induced along with interferon (IFN)–γ
and tumor necrosis factor (TNF), pro-
inflammatory cytokines with a patho-
genic role in EAE, we investigated the
effect of IFN-γ and TNF on EPO expres-
sion in neuronal and glial cells. The re-
sults indicate that EPO is induced dur-
ing EAE and is negatively regulated by
IFN-γ and TNF.
MATERIALS AND METHODS
Animal Experiments
Procedures involving animals and
their care were conducted in conformity
with the institutional guidelines in com-
pliance with national and international
laws and policies (17–19). The protocols
for the proposed investigation were re-
viewed and approved by the Animal
Care and Use Committees (IACUC) of
the Mario Negri Institute for Pharmaco-
logical Research.
Chronic EAE was induced in female
C57BL/6 mice (6–8 wks; Harlan, Bresso,
MI, Italy) by subcutaneous (s.c.) immu-
nization with 200 μg of MOG peptide
35–55 (Multiple Peptide Systems, San
Diego, CA, USA) per mouse in incom-
plete Freund’s adjuvant (Sigma, St Louis,
MO, USA) supplemented with 8 mg/mL
of M. tuberculosis (H37Ra; Difco Labora-
tories, Detroit, MI, USA). Mice received
500 ng of pertussis toxin (Sigma) intra-
venously (i.v.) at the time of immuniza-
tion and 48 h later. Clinical score was re-
corded daily as described elsewhere (6).
Relapsing-remitting EAE was induced
in female 8- to 12-wk-old SJL mice
(Charles River, Calco, LC, Italy) by s.c.
immunization with PLP peptide 139–151
(100 μg/mouse, in incomplete Freund’s
adjuvant, Sigma, containing 2 mg/mL
of heat-killed M. tuberculosis, Difco) as
described (16).
Real-Time RT-PCR
Total RNA was extracted from spinal
cords or cell cultures using the TRIzol
reagent (Invitrogen, Carlsbad, CA, USA),
retrotranscribed according to standard
procedures, and amplified by real-time
reverse-transcription (RT)-PCR. All pro-
cedures were performed on the ABI
PRISM 7300 Sequence Detection System
(Applied Biosystems, Foster City, CA,
USA). For quantification, we used the
comparative threshold cycle (ΔCt)
method, according to the manufacturer’s
guidelines. EPO mRNA was analyzed by
the TaqMan method, with gene expres-
sion assays for EPO and GAPDH (house-
keeping gene) commercially available
from Applied Biosystems. Data were ex-
pressed as EPO mRNA units, with a
cDNA from mouse kidney used as a cali-
brator (or rat kidney when EPO mRNA
was measured in rat glial cells). IFN-γ
and TNF mRNA levels were analyzed by
the SYBR Green method, with primer se-
quences for TNF, IFN-γ, and GAPDH as
reported (20). Data were expressed as
fold induction versus control mice, using
one of the controls as a calibrator.
Immunohistochemistry
Animals were sacrificed by intracardial
perfusion (21). EPO localization was
evaluated along the whole length of the
spinal cord. Sections (40 μm-thick) were
washed in phosphate-buffered saline
(PBS), incubated in 10% blocking serum
in PBS at room temperature and exposed
to polyclonal rabbit anti-EPO (1:100, 
H-162, Santa Cruz Biotechnology, Hei-
delberg, Germany) in 2% goat sera at 
4° C. After an overnight incubation, the
sections were incubated with biotiny-
lated goat anti-rabbit antibodies (1:100,
Vector Laboratories Inc., Burlingame,
CA, USA) for 60 min, revealed with
avidin-biotin using a peroxidase kit (Vec-
tastain Elite, Vector), and the signal visu-
alized with diaminobenzidine (DAB;
Sigma Chemical, Deisenhofen, Germany)
under a light microscope.
Free floating immunofluorescence ex-
periments were carried out on 30 μm-
thick lumbar spinal cord (L2–L3) sections.
Coronal sectioning was preferred to bet-
ter evaluate the localization of the differ-
ent markers in specific areas of the grey
matter. EPO was detected with poly-
clonal rabbit anti-EPO and biotinylated
goat anti-rabbit antibodies as described
above, and the immunofluorescence re-
vealed with Alexa 488 goat anti-rabbit
secondary antibody (1:1000, Molecular
Probes, Eugene, OR, USA). Neurons were
stained with 530-615 NeuroTrace Fluores-
cent Nissl reagent (1:5000, Molecular
Probes). Astrocytes were identified by a
mouse anti-GFAP monoclonal antibody
(1:1000, Immunological Science, Rome,
Italy) followed by an Alexa 546 goat anti-
mouse secondary antibody (1:1000, Mole-
cular Probes). Sections were observed
with an Olympus Fluoview microscope
BX61 with confocal system FV500. To
confirm the specificity of the signal, we
checked that incubating with either a pri-
mary or a secondary antibody alone gave
no staining (not shown).
Cell Culture
Human Kelly neuroblastoma cells
were cultured and stimulated with the
HIF-inducer deferoxamine mesylate
(DFX, Sigma) as reported (22), with or
without recombinant human IFN-γ (Hy-
Cult Biotechnology, Uden, The Nether-
lands) or recombinant human TNF-α
(R&D Systems, Minneapolis, MN, USA).
After 24 h of incubation, EPO was mea-
sured in the supernatant by Enzyme-
Linked ImmunoSorbent Assay (ELISA)
(Quantikine EPO, R&D Systems, sensi-
tivity 0.6 mU/mL). All samples were as-
sayed in duplicate. Results were ex-
pressed as mU/mL.
Primary cultures of glial cells were
prepared from 1- to 2-d-old newborn rats
(Sprague-Dawley, Charles River) as de-
scribed (3). Cells were treated for 24 h
with the HIF-inducer dimethyloxalyl-
glycine (DMOG, Frontier Scientific Inc.,
Logan, UT, USA), with or without re-
combinant rat IFN-γ (R&D Systems) or
recombinant rat TNF-α (R&D Systems),
then total RNA was extracted and ana-
lyzed for EPO expression by real-time
RT-PCR.
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RESULTS
EPO Expression Is Increased in the
Spinal Cord of Mice with EAE
In chronic EAE induced by immuniza-
tion of C57BL/6 mice with MOG35-55,
clinical signs of disease have an onset at
d 10-15 after immunization, peak at d 20,
and then stabilize (6). By quantitative
real-time RT-PCR, we found a marked
increase in EPO mRNA expression in the
spinal cord of mice with EAE at d 20 as
compared with control naive mice (Fig-
ure 1A). EPO mRNA levels remained ele-
vated at d 40, when the clinical signs of
the disease are stabilized.
In SJL mice, PLP139-155-induced EAE
is characterized by a relapsing-remitting
type of disease (16). In this model, EPO
expression was increased in the spinal
cord at the peak of the disease, and re-
mained elevated in the remission phase
(Figure 1B).
Immunohistochemical Localization of
EPO in the Spinal Cord
Immunohistochemistry on d 20 after
immunization of C57BL/6 mice re-
vealed an almost selective immunoreac-
tivity in the gray matter (central layer),
with a spot pattern, and a very low
staining in the white matter (external
layers) (Figure 2A). Higher magnifica-
tion of the area corresponding to the
ventral horns showed that EPO is local-
ized in cell bodies of neurons with dif-
ferent sizes, likely motoneurons and in-
terneurons (Figure 2B). Although DAB
immunohistochemistry does not allow a
quantitative evaluation, staining inten-
sity of large-sized neurons appears
higher in EAE mice (Figure 2B) com-
pared with healthy controls (Figure 2C).
Incubation of sections without the pri-
mary antibody allowed us to exclude
the presence of a non-specific im-
munoreactivity due to the biotinylated
secondary antibody (not shown).
When Nissl was used to identify neu-
rons (Figure 2D, red), EPO staining
(Figure 2E, green) co-localized with it
(Figure 2F, merge), showing a cytoplas-
mic localization. On the other hand, co-
localization experiments using GFAP to
stain astrocytes (Figure 2G, red) and
EPO (Figure 2H, green) confirmed the
lack of expression of EPO by astrocytes
(Figure 2I, merge).
HIF-1α Expression Is Induced in EAE
We investigated the mRNA expression
of HIF-1α and HIF-2α in the spinal cord
of mice with chronic EAE (C57BL/6) or
relapsing-remitting EAE (SJL), and corre-
lated it with the increased expression of
EPO mRNA. For purpose of comparison,
we also measured HIFs and EPO mRNA
in the spinal cord of mice treated with
phenylhydrazine (PhH), which also is
known to induce EPO expression in the
CNS (23). In both models of EAE, a sig-
nificant increase of HIF-1α, but not
HIF-2α, expression was observed (Fig-
ure 3), accompanied by a two- to three-
fold induction in EPO mRNA (see above
and Figure 3). On the contrary, PhH did
not increase spinal cord HIF-1α and 
HIF-2α mRNA, even though it strongly
induced EPO expression (controls, 0.11 ±
0.02; PhH, 1.01 ± 0.15; P < 0.001, n = 4),
acting through stabilization of the HIF
protein, as reported (24).
IFN-γ and TNF Are Co-Induced with
EPO and Inhibit its Expression in
Neuronal and Glial Cells in vitro
We also measured the expression of
the two inflammatory cytokines IFN-γ
and TNF in the spinal cord. This was
high at the peak of the disease and then,
unlike EPO, declined both in chronic
EAE in C57BL/6 mice (Figure 4A,4B)
and in relapsing-remitting EAE in SJL
mice (Figure 4C,4D).
The temporal co-induction of EPO,
IFN-γ, and TNF in the spinal cord
prompted us to investigate the effect of
these cytokines on EPO expression in
neuronal cells. To this end, we used Kelly
human neuroblastoma cells, known to
produce significant amounts of EPO pro-
tein, detectable by ELISA (22). IFN-γ or
TNF, alone or in combination, did not in-
duce EPO production in Kelly cells (not
shown). On the contrary, when EPO was
induced with the HIF-stabilizer DFX,
IFN-γ dose-dependently inhibited DFX-
induced EPO secretion (Figure 5A). TNF
alone did not affect DFX-induced EPO
production, but synergized with IFN-γ
(Figure 5B). The observed synergy is con-
sistent with the hypothesis that lack of
inhibition by TNF alone could be due, at
least partially, to low expression of TNF
receptor 1 (TNFR1), which is known to
be induced by IFN-γ. In fact, we found
that, in our conditions, IFN-γ increased
Figure 1. EPO expression in EAE. EPO mRNA
was measured in the spinal cord of con-
trol and C57BL/6 mice with MOG-induced
chronic EAE at the indicated day after the
immunization (A) or SJL mice with PLP-
induced relapsing-remitting EAE at the
peak of the disease, d 14–15 after immu-
nization, and in the remission phase, on 
d 19–30 after immunization (B). The clinical
score of the disease is indicated below
each panel. Results are the mean ± stan-
dard error of mean (SEM) of values of at
least 10 mice per group (A) and at least 5
mice per group (B), with individual sam-
ples tested in duplicate. *P < 0.05; ***P <
0.001 versus control, Student t test.
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TNFR1 mRNA levels at 4 h (three-fold
induction measured by real-time RT-
PCR, data not shown).
Although immunolocalization of EPO
in EAE suggests it is produced mainly
by neurons, others reported that glial
cells also express EPO (10,11,25,26). We
thus studied the effect of IFN-γ and TNF
on EPO expression in rat primary glial
cells, where EPO was induced with the
HIF-stabilizer DMOG. In these experi-
ments, EPO was measured by RT-PCR
because its levels in the culture super-
natants were undetectable by ELISA. As
shown in Figure 5, panels C and D, both
IFN-γ and TNF markedly and dose-
dependently inhibited EPO expression
in glial cells.
DISCUSSION
While administration of EPO is protec-
tive in models of EAE (1,4–6) and possi-
bly in MS patients (7), as well as in other
CNS diseases (1,2), induction of endoge-
nous EPO in the CNS has only been re-
ported for hypoxic/ischemic pathologies,
where EPO is induced as a result of the
activation of HIF by hypoxia (10–12).
Our study shows that EPO is ex-
pressed in the CNS of mice with EAE,
and immunohistochemistry indicated
that it was associated mainly with neu-
rons. The finding that neuronal cells are
the main source of EPO expression in
the spinal cord is in agreement with a
previous study in the development of
CNS (27).
In consideration of the anti-inflammatory
action of exogenous EPO administration
in EAE (6), the induction of endogenous
EPO reported here suggests that EPO
may be part of a protective response,
along with anti-inflammatory cytokines
such as interleukin-4 (IL-4), interleukin-10
(IL-10), and transforming growth factor
(TGF)-β—whose expression correlates
with recovery from EAE (28–30). Of note,
considering the neuronal localization of
EPO expression, others reported that
neurons can express neurotrophic or pro-
tective cytokines: motoneurons can ex-
press brain-derived neurotrophic factor
(BDNF) (31), and TGF-β is expressed by
Figure 2. Immunohistochemical localization of EPO in the spinal cord. (A) Representative
picture showing the pattern of EPO staining along the spinal cord in chronic EAE, 20 d
after immunization. The more caudal part of the spinal cord, representing the lumbar
tract, is on the left of the picture, and the thoracic regions are on the right. (B–C) Higher
magnification pictures showing EPO in the ventral horns of the lumbar spinal cord in EAE
(B) and a control mouse (C). (D–F) Nissl staining (D), EPO (E), and their colocalization (F),
in the anterior horns of the lumbar spinal cord in EAE. (G–I) GFAP (G), EPO (H), and the
merging field obtained by the overlapping of both signals (I), in the anterior horns of the
lumbar spinal cord in EAE. Scale bars: A, 500 μm; B–C, 80 μm; D–F, 50 μm; G–I, 60 μm.
Figure 3. HIF-1α expression is induced in EAE. HIF-1α mRNA was measured in the spinal
cord of control and C57BL/6 mice with MOG-induced EAE at d 20 after immunization 
(A), SJL mice with PLP-induced EAE at the peak of the disease, d 14–15 after immuniza-
tion (B) or C57BL/6 healthy mice 24 h after treatment with phenylhydrazine (PhH; 150 mg/Kg,
i.p., panel C). In the same mice, HIF-2α mRNA was also measured (D–F). EPO mRNA lev-
els, expressed as fold induction versus control, are indicated below. Results are the
mean ± SEM (n = 5: panels A,B,D,E; n = 4: panels C,F), with individual samples tested in
duplicate. *P < 0.05; **P < 0.01; ***P < 0.001 versus control, Student t test.
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neurons during the remission phase of
EAE (30).
The protective action of EPO in MS
may be exerted also on other pathways
than the inflammatory cytokine network.
In fact, others have shown upregulation
of VEGF, another target of HIF-1α, in the
spinal cords of rats with EAE (32) and in
MS active plaques from autopsy samples
(14,32), and it was suggested that upreg-
ulated VEGF in MS might contribute to
the increased permeability of the blood-
brain barrier (32). In this context, EPO
was reported to counteract the increase
in permeability induced by VEGF in an
in vitro model of blood-brain barrier (33).
The mechanisms that upregulate EPO
expression in EAE remain to be eluci-
dated. The hypoxia-induced upregulation
of EPO is modulated at the transcrip-
tional level by HIF. The predominant
mode of HIF induction by hypoxia is at
the level of protein stability. In particular,
the α subunits of HIF (HIF-1α and HIF-2α)
are stabilized and accumulate upon hy-
poxia (34). In addition, several in vivo
studies showed increased levels of HIF-1α
mRNA (35,36). We found that EPO induc-
tion in EAE is paralleled by an elevation
of HIF-1α, but not HIF-2α, mRNA. Of
note, PhH, that induces EPO expression
in the CNS secondary to anemia (23), had
no effect on HIF-1α mRNA even if EPO
induction was more marked than in EAE,
confirming previous studies showing that
it acts by increasing HIF at the protein
level (24). Indeed PhH even decreased
HIF-2α expression, possibly through a
negative feedback mechanism.
Recently, possible mechanisms for
HIF-1α mRNA induction by hypoxia
have been characterized (37), and it also
has been reported that non-hypoxic in-
flammatory mediators, including reac-
tive oxygen species, may activate HIF-1α
at the transcriptional level, possibly
through NF-κB induction (38). In particu-
lar, inflammatory stimuli can induce
HIF-1α mRNA in macrophages (39) and
microglial cells (40), and these mecha-
nisms might play a role in the increase of
EPO expression in EAE. Of note, the ef-
fect of inflammatory stimuli on HIF tran-
Figure 4. Expression of IFN-γ and TNF in EAE. IFN-γ and TNF expression in spinal cords of
C57BL/6 mice with MOG-induced EAE (A,B), or in SJL mice with PLP-induced EAE (C,D) at
the time points described in the legend to Figure. 1. Results (fold induction [FI] versus con-
trol) are the mean ± SEM of values of at least 10 mice per group (A,B) and at least 5 mice
per group (C,D), with individual samples tested in duplicate. *P < 0.05; **P < 0.01; ***P <
0.001 versus control, Student t test.
Figure 5. EPO expression is downregulated by inflammatory cytokines in vitro. Kelly neurob-
lastoma cells were incubated for 24 h with 200 μM deferoxamine mesylate (DFX) in the
presence or absence of IFN-γ (A), or TNF at the indicated concentrations (10 or 100 ng/mL),
with or without preincubation with 10 U/mL IFN-γ (B), and EPO secretion was measured by
ELISA. Rat glial cells were incubated for 24 h with 500 μM dimethyloxalylglycine (DMOG)
and the indicated concentrations of IFN-γ (C) or TNF (D), and EPO expression was ana-
lyzed by real-time RT-PCR. Results are the mean ± SEM of triplicate samples tested in
duplicate. *P < 0.05; **P < 0.01; ***P < 0.001 versus DFX or DMOG alone; #P < 0.01 versus
DFX + IFN-γ; Student t test.
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scriptional activity in macrophages is
mediated by specific increase of HIF-1α,
and not HIF-2α, mRNA (39), paralleling
our finding in the inflamed spinal cord
in EAE.
Interestingly, we also show that TNF
and IFN-γ inhibit EPO expression in neu-
ronal and glial cell, in agreement with
previous reports showing an inhibitory
effect of inflammatory cytokines on EPO
expression outside the CNS (41). These
data, together with the known inhibitory
effect of EPO on neuroinflammation (3,6),
reveal a cross-talk between EPO and in-
flammatory cytokines in the CNS, out-
lined in Figure 6. This circuit may have
important implications in the pathogene-
sis of CNS inflammatory diseases, and
could be exploited therapeutically with
strategies aimed at upregulating the
EPO-mediated protective response.
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